Prostate Cancer in Primary Care by Merriel, Samuel W D et al.
                          Merriel, S. W. D., Funston, G., & Hamilton, W. (2018). Prostate Cancer in
Primary Care. Advances in Therapy, 35(9), 1285–1294.
https://doi.org/10.1007/s12325-018-0766-1
Publisher's PDF, also known as Version of record
Link to published version (if available):
10.1007/s12325-018-0766-1
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Springer at
https://doi.org/10.1007/s12325-018-0766-1 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
REVIEW
Prostate Cancer in Primary Care
Samuel W. D. Merriel . Garth Funston . Willie Hamilton
Received: July 3, 2018 / Published online: August 10, 2018
 The Author(s) 2018
ABSTRACT
Prostate cancer is a common malignancy seen
worldwide. The incidence has risen in recent
decades, mainly fuelled by more widespread use
of prostate-specific antigen (PSA) testing,
although prostate cancer mortality rates have
remained relatively static over that time period.
A man’s risk of prostate cancer is affected by his
age and family history of the disease. Men with
prostate cancer generally present symptomati-
cally in primary care settings, although some
diagnoses are made in asymptomatic men
undergoing opportunistic PSA screening.
Symptoms traditionally thought to correlate
with prostate cancer include lower urinary tract
symptoms (LUTS), such as nocturia and poor
urinary stream, erectile dysfunction and visible
haematuria. However, there is significant
crossover in symptoms between prostate cancer
and benign conditions affecting the prostate
such as benign prostatic hypertrophy (BPH) and
prostatitis, making it very challenging to dis-
tinguish between them on the basis of symp-
toms. The evidence for the performance of PSA
in asymptomatic and symptomatic men for the
diagnosis of prostate cancer is equivocal. PSA is
subject to false positive and false negative
results, affecting its clinical utility as a stan-
dalone test. Clinicians need to counsel men
about the risks and benefits of PSA testing to
inform their decision-making. Digital rectal
examination (DRE) by primary care clinicians
has some evidence to show discrimination
between benign and malignant conditions
affecting the prostate. Patients referred to sec-
ondary care for diagnostic testing for prostate
cancer will typically undergo a transrectal or
transperineal biopsy, where a number of sam-
ples are taken and sent for histological exami-
nation. These biopsies are invasive procedures
with side effects and a risk of infection and
sepsis, and alternative tests such as multipara-
metric magnetic resonance imaging (mpMRI)
are currently being trialled for their accuracy
and safety in diagnosing clinically significant
prostate cancer.
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INTRODUCTION
Prostate cancer is the second most common
cancer diagnosed in men globally, after lung
cancer. Despite relatively high survival rates for
men with prostate cancer, more than 300,000
prostate cancer deaths occurred in 2012 world-
wide. Age and family history are key risk factors
for prostate cancer, and black men have a
higher risk of prostate cancer incidence and
death compared to men from white or Asian
backgrounds [1].
The majority of cases of prostate cancer are
diagnosed in men from western countries in the
Americas and Europe, and this has largely been
driven by the introduction of prostate-specific
antigen (PSA) for prostate cancer detection in the
1990s. The widespread use of PSA has proven
controversial as the evidence for benefit as a
screening test in asymptomatic men is still sub-
ject to debate, and PSA is prone to false positives
and false negatives in men with symptoms sug-
gestive of a possible diagnosis of prostate cancer
[2]. Work is ongoing to find better ways to risk
stratify men for further investigation, and more
accurate methods to differentiate between clini-
cally significant and clinically insignificant pros-
tate cancer to inform treatment decisions.
Most prostate cancer diagnoses are made in
symptomatic men. Prostate cancer should be
suspected in men over 50 years old presenting
with lower urinary tract symptoms (LUTS), vis-
ible haematuria or erectile dysfunction [3].
LUTS are also a common presenting symptom
of benign conditions affecting the prostate,
such as benign prostatic hyperplasia (BPH) and
prostatitis, creating a diagnostic challenge.
There is no strong evidence of association
between the severity of LUTS and the likelihood
of prostate cancer or the stage at diagnosis [4].
Digital rectal examination (DRE) is recom-
mended in many countries alongside PSA to aid
decision-making about referral for diagnostic
testing. A recent systematic review suggests that
DRE has a high specificity and positive predic-
tive value (PPV) for prostate cancer in symp-
tomatic patients [5].
In light of the limitations of PSA, a number
of other tests have been investigated to aid the
diagnosis of clinically significant prostate can-
cer. PSA is a kallikrein serine protease, and other
related biomarkers have been assessed for a
potential role in prostate cancer detection [6].
Genome-wide association studies (GWAS) have
identified more than 100 single nucleotide
polymorphisms (SNPs) related to risk of prostate
cancer [7]. Multiparametric magnetic resonance
imaging (mpMRI) has gained much interest in
recent years, both as a diagnostic test for pros-
tate cancer and for monitoring men with loca-
lised prostate cancer on active surveillance for
signs of disease progression [8].
This article will outline the epidemiology of
prostate cancer, an approach to diagnosis, and
further investigations and referral criteria. This
article is written by general practitioners (GPs)
in the UK, but will be of relevance to primary
care practitioners working in other healthcare
systems. This article is based on previously
conducted studies and does not contain any
studies with human participants or animals
performed by any of the authors.
EPIDEMIOLOGY AND RISK
FACTORS
Approximately 1.1 million men were diagnosed
with prostate cancer in 2012, with over 70% of
these men being from high-income countries.
Age-standardised incidence rates are highest in
Australia and New Zealand (111.6 per 100,000
men), North America (97.2), and Western Eur-
ope (85.8), and lowest in South (4.5) and Wes-
tern (10.5) Asian regions. Prostate cancer is the
fifth leading cause for cancer death in men
worldwide, with the highest mortality rates in
countries with predominantly black ethnic
populations such as the Caribbean (29 per
100,000 males) and Africa (19.9) [1]. Mortality
rates from prostate cancer have generally
decreased globally in the last decade, with the
exception of a few Northern European and
Asian countries [9].
Prostate cancer incidence relates strongly to
age, with age-specific incidence rates rising
sharply from the age of 50 years and being
highest in men aged 90 and above, according to
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Office for National Statistics data from the UK
[10]. A positive family history significantly
affects a man’s risk of prostate cancer. Pooled
risk estimates suggest that a man with one first-
degree relative (father or brother) with a diag-
nosis of prostate cancer has a relative risk of
2.48 (95% CI 2.25–2.74), rising to 4.39 (95% CI
2.61–7.39) for men with two or more first-de-
gree relatives affected by the disease [11]. The
evidence for an association between prostate
cancer and heritable germline mutations such
as BRCA1 [12, 13] and Lynch syndrome [14] is
more mixed.
Men from African and Caribbean ethnic
backgrounds have the highest prostate cancer
incidence and mortality rates compared to
other ethnic groups. The lifetime risk of prostate
cancer in black UK men is double that of white
UK men and three times the risk of men from
Asian backgrounds [15]. Relative to white men,
men of African or Caribbean descent have a
worse prognosis in the USA [16] and the UK
[17]. There are no known modifiable risk factors
for prostate cancer.
SYMPTOMS AND SIGNS
Prostate cancer is detected in men in a number of
ways. The widespread use of PSA as a screening
test for prostate cancer in some countries has led
to increasing diagnoses being made in asymp-
tomatic men. Men may present to their doctor
complaining of LUTS or other genito-urinary
symptoms, and are thus investigated for prostate
cancer. It also is suspected that there are a sig-
nificant number of men who go through life and
die with undiagnosed prostate cancer; this suspi-
cion is based on the findings of autopsy studies
showing that up to three quarters of men over the
age of 85 had neoplastic changes in the prostate,
not all of whom had been diagnosed prior to their
death [18].
LUTS are very common as men get older, with
studies estimating a prevalence of greater than
50% in men aged 50 years and above, increasing
further with increasing age [19]. LUTS are broadly
divided into three categories: storage, voiding,
and post-micturition symptoms (see Table 1).
LUTS are generally associated with possible
prostate cancer by clinicians and patients alike,
although there is no strong evidence for this [4].
Studies have found an increased risk of localised
prostate cancer in men with LUTS, but no asso-
ciation between LUTS and advanced prostate
cancer [20–22]. It is thought that patients pre-
senting to their doctor with LUTS are at higher
risk of being diagnosed with prostate cancer as a
result of higher rates of testing, and are mainly
diagnosed with early stage prostate cancer which
may or may not affect their long-term mortality
risk [21].
Other genito-urinary symptoms may also
suggest that an undiagnosed prostate cancer is
present. Visible haematuria is well established
as a high-risk symptom for possible urological
cancer, including prostate cancer [23, 24].
Erectile dysfunction, another symptom that is
very common in men and increases in preva-
lence with increasing age, has also been shown
to be associated with prostate cancer [25, 26].
The majority of studies of prostate cancer
diagnosis in symptomatic patients have been
conducted in secondary care. They do not
demonstrate any symptom that can distinguish
prostate cancer from BPH, but suggest that DRE
and/or PSA may help to differentiate between the
two [27]. A UK case–control study of primary care
patients comparing men diagnosed with prostate
cancer to age-matched controls showed that
Table 1 Categories of LUTS. Adapted from [20]
LUTS category Symptoms
Voiding Poor stream
Intermittent stream
Hesitancy
Straining to void
Terminal dribbling
Storage Frequency
Nocturia
Urgency
Urge incontinence
Post-micturition Incomplete emptying
Post-micturition dribble
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many individual LUTS (nocturia, hesitancy, fre-
quency/urgency, and urinary retention) each had
a positive predictive value (PPV) of 2.2–3.1%, and
impotence had a PPV of 3.0% [26]. A risk of sus-
pected cancer of 3% or more warrants referral for
further investigation according to the National
Institute for Health and Care Excellence (NICE) in
the UK, meaning that many LUTS meet this
threshold for prostate cancer.
DRE in the diagnosis of prostate cancer in
primary care is also somewhat controversial, but
has some stronger evidence for its use. Hamil-
ton et al. [26] found a PPV of 12% (95% CI 5.37)
for an abnormal DRE deemed to be malignant
by a GP, and a recently published systematic
review of all studies of DRE for prostate cancer
diagnosis in symptomatic patients in primary
care found a pooled PPV of 42.3% [5]. This data
suggests that, despite the reservations of some
doctors in performing DREs, primary care clin-
icians can differentiate between a benign and
malignant prostate on examination to a con-
siderable extent.
Guidelines from the American Urological
Association [28] and the European Association
of Urology [29] focus on the role of PSA in the
early detection of prostate cancer. The NICE
guidance for ‘Suspected cancer: recognition and
referral’ makes recommendations for clinicians
to refer patients on the ‘suspected cancer refer-
ral pathway’ on the basis of symptoms, DRE
findings, and/or PSA (Table 2).
INVESTIGATIONS
Debate continues around the role of PSA in the
early detection and diagnosis of prostate cancer.
As a screening test for prostate cancer in
asymptomatic men, the three major trials to
date have produced conflicting results (Table 3).
All three studies show an increase in prostate
cancer diagnosis in the intervention group, but
only the European Randomised Study of
Screening for Prostate Cancer (ERSPC) trial
shows a reduction in prostate cancer mortality.
None of the three trials showed a clear change
in overall mortality, although there was some
contamination of the control in the Prostate,
Lung, Colorectal, and Ovarian (PLCO) study
that might have affected the results [30]. Cau-
tion needs to be taken in comparing the Cluster
Table 2 Extract from the NICE suspected cancer: recognition and referral guidelines (NG12) 2015 [3]
1.6.1 Refer men using a suspected cancer referral pathway (for an appointment within 2 weeks) for prostate cancer if
their prostate feels malignant on digital rectal examination
1.6.2 Consider a prostate-speciﬁc antigen (PSA) test and digital rectal examination to assess for prostate cancer in men
with:
Any lower urinary tract symptoms, such as nocturia, urinary frequency, hesitancy, urgency or retention or
Erectile dysfunction or
Visible haematuria
1.6.3 Refer men using a suspected cancer referral pathway (for an appointment within 2 weeks) for prostate cancer if
their PSA levels are above the age-speciﬁc reference range
Table 3 Summary table of major PSA screening trials
Trial Population Prostate cancer diagnosis
rate ratio (95% CI)
Prostate cancer death
rate ratio (95% CI)
CAP, 2018 [33] 415,357 UK men 1.19 (1.14, 1.25) 0.96 (0.85, 1.08)
PLCO, 2017 [34] 76,683 US men 1.22 (1.16, 1.29) 1.04 (0.87, 1.24)
ERSPC, 2014 [35] 182,160 European men 1.57 (1.51, 1.62) 0.79 (0.69, 0.91)
1288 Adv Ther (2018) 35:1285–1294
Randomised Trial of PSA Testing for Prostate
Cancer (CAP) trial to PLCO and ERSPC, as CAP
used a one-off PSA screening test rather than
regular PSA testing. A Cochrane review by Ilic
et al., last updated in 2013, found no evidence
for a reduction in prostate cancer mortality as a
result of screening, and found that harms asso-
ciated with PSA-based screening were common
and could be severe [31]. The US Preventive
Services Taskforce recommended against PSA-
based prostate cancer screening for men over
70 years and or for men who do not express a
preference for screening, but suggests that the
decision to undergo screening with PSA should
be an individual one for the patient after
counselling from their doctor on the pros and
cons of the test [2]. A recent consensus meeting
of European experts recommended that limited
prostate cancer screening should be rolled out
[32].
PSA does have some utility for symptomatic
patients as a marker of prostate cancer [36],
although some caution is needed. PSA levels can
be raised by a number of benign conditions,
including BPH, prostatitis, ejaculation, and
exercise (false positive). PSA can be within the
normal range for up to 25% of men with pros-
tate cancer (false negative) [37]. Urine dipstick
testing, with or without microscopy, culture
and sensitivities (MC&S) should be performed
prior to PSA testing to rule out lower urinary
tract infection [3]. Patients need to be made
aware of the limitations of PSA, and the result
needs to be considered in the wider context of
the presence or absence of symptoms, the
examination findings, and the patient’s co-
morbidities and life expectancy. Using patient
decision aids can support these discussions, and
there is evidence to show that they improve
men’s knowledge of PSA, reduce decisional
conflict/distress, and increase decisional satis-
faction [38]. Table 4 includes some of the more
commonly used PSA decision aids used in clin-
ical practice.
Table 4 Examples of patient decision aids for PSA testing
Country Decision aid
USA American Society of Clinical Oncology
‘Decision aid tool: Prostate cancer screening with PSA testing’
https://www.asco.org/sites/new-www.asco.org/ﬁles/content-ﬁles/practice-and-guidelines/documents/2012-psa-
pco-decision-aid.pdf
Healthwise
‘Prostate cancer screening: Should I have a PSA test?’
https://www.healthwise.net/cochranedecisionaid/Content/StdDocument.aspx?DOCHWID=aa38144
Australia Royal Australian College of General Practitioners
‘Should I have prostate cancer screening?’
https://www.racgp.org.au/download/Documents/Guidelines/prostate-cancer-screening-infosheetpdf.pdf
Europe Societe Internationale D’Urologie
‘PSA screening decision-making aid: For patients, general practitioners and urologists’
https://www.siuurology.org/themes/web/assets/ﬁles/society/psa_testing_brochure.pdf
UK Public Health England
‘PSA testing and prostate cancer: advice for well men aged 50 and over’
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/ﬁle/509191/
Patient_info_sheet.pdf
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The current gold standard diagnostic test for
prostate cancer is a prostate biopsy, usually via a
transrectal (TRUS) or transperineal approach
guided by ultrasound. Primary care clinicians
suspecting prostate cancer after assessing a
patient or finding an elevated PSA result should
refer on a cancer pathway to their local uro-
logical service for diagnostic testing. Multiple
cores from various regions of the prostate are
taken and sent for histological analysis and
tumour grading. This approach also has some
limitations through missing some clinically
significant prostate cancers and detecting some
clinically insignificant cancers. Complications,
such as haematuria and haematospermia, and
infection as a result of biopsy are not uncom-
mon [39].
RISK PREDICTION MODELS
Numerous risk prediction models and nomo-
grams for calculating a man’s risk of prostate
cancer have been developed, including the
Prostate Cancer Prevention Trial (PCPT) risk
calculator [40] and the ERSPC risk calculator
[41]. Louie and colleagues identified over 100
such models, and found that only six models
predicting any prostate cancer (as opposed to
clinically significant prostate cancer) had been
thoroughly validated. None had been assessed
for their effectiveness in clinical practice [42].
The vast majority of these risk calculators have
been developed and validated using secondary
care data [43, 44], and most attempt to predict
biopsy outcome on the basis of pre-biopsy data.
The European guidelines state that risk predic-
tion models may be useful in reducing unnec-
essary biopsies on an individual case basis [29],
and the US [28] and UK [45] guidelines make no
mention of their utility in the early detection of
prostate cancer.
DIAGNOSTIC APPROACH
IN PRIMARY CARE
Examples of three common case scenarios are
given in Fig. 1a–c.
THE FUTURE
A number of new tests and testing strategies are
being trialled to improve the diagnosis of clin-
ically significant prostate cancer. There is some
evidence for mpMRI in a number of applica-
tions in prostate cancer. Recent studies suggest
that mpMRI is more accurate in diagnosing
prostate cancer compared to TRUS biopsy
[8, 46]; that mpMRI can improve the accuracy
of biopsies of suspicious prostate lesions [47];
and mpMRI may be able to better distinguish
between clinically significant and clinically
insignificant prostate cancer [8]. Studies are
currently underway to assess the utility of
mpMRI in active surveillance for men with low-
grade, localised tumours [48]. All these studies
so far have been conducted in secondary or
tertiary level settings.
Blood-based biomarkers for prostate cancer
are also being extensively investigated. The
Stockholm3 model (STHLM3) is a risk-based
model incorporating clinical data, DRE find-
ings, plasma protein biomarkers (PSA, free PSA,
intact PSA, hK2, MSMB, and M1C1), and 232
SNPs. In a Swedish population study, STHLM3
outperformed PSA alone in predicting clinically
significant prostate cancer defined as Gleason
grade of 7 or above [area under receiver oper-
ating characteristic curve (AUC) 0.74, 95% CI
0.72–0.75 vs 0.56, 95% CI 0.55–0.60] [49]. Val-
idation studies of STHLM3 in other countries
are ongoing. The 4K test consists of four kal-
likrein proteins [total PSA, free PSA, intact PSA,
and human kallikrein 2 (hK2)], and has also
been shown to have applications in identifying
clinically significant prostate cancer [6, 50, 51].
CONCLUSIONS
Prostate cancer presents a number of challenges
for primary care clinicians. Many men with
prostate cancer are asymptomatic until the
tumour has progressed, and common symp-
toms have significant crossover with benign
conditions affecting the prostate. The disease is
highly prevalent with a relatively lower mor-
tality rate, necessitating the search for ways to
identify clinically significant prostate cancer
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requiring invasive treatment to improve sur-
vival. There are currently no widely available
tests or strategies that have strong evidence for
differentiating between clinically significant
and clinically insignificant prostate cancer.
Current diagnostic tests have limitations in
terms of significant false positive and false
negative rates. Research is ongoing into better
methods for diagnosing prostate cancer.
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